Skip to content

PROVECTUS BIOPHARMACEUTICALS, INC.: 10-Q filed 2026-08-13

What PROVECTUS BIOPHARMACEUTICALS, INC. reported in its quarterly report filed 2026-08-13 (fiscal Q2 2026): 38 published measures, 107 facts as tagged in accession 0001493152-26-037671.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-13
Fiscal period
fiscal Q2 2026
Accession
0001493152-26-037671 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PROVECTUS BIOPHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-301,473,501USD
At 2025-12-31697,502USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-307,761,065USD
At 2025-12-317,000,220USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-30-6,275,171USD
At 2025-12-31-6,298,737USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-06-301,156,915USD
At 2025-06-30385,929USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-982,566USD91
2026-01-01 to 2026-06-30-2,273,020USD181
2025-04-01 to 2025-06-30-1,814,420USD91
2025-01-01 to 2025-06-30-2,954,528USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-715,814USD181
2025-01-01 to 2025-06-30-1,616,571USD181

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2025-04-01 to 2025-06-3057,480USD91
2025-01-01 to 2025-06-30336,108USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-301,621,050USD181
2025-01-01 to 2025-06-301,542,874USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-265,126,832USD
At 2025-12-31-262,853,812USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-30420,279,879shares91
2026-01-01 to 2026-06-30420,279,879shares181
2025-04-01 to 2025-06-30420,279,879shares91
2025-01-01 to 2025-06-30420,279,879shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-04-01 to 2026-06-30420,279,879shares91
2026-01-01 to 2026-06-30420,279,879shares181
2025-04-01 to 2025-06-30420,279,879shares91
2025-01-01 to 2025-06-30420,279,879shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-300USD/shares91
2026-01-01 to 2026-06-30-0.01USD/shares181
2025-04-01 to 2025-06-300USD/shares91
2025-01-01 to 2025-06-30-0.01USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-04-01 to 2026-06-300USD/shares91
2026-01-01 to 2026-06-30-0.01USD/shares181
2025-04-01 to 2025-06-300USD/shares91
2025-01-01 to 2025-06-30-0.01USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2026-06-302,068USD
At 2025-12-313,000USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-06-30611,995USD181
2025-01-01 to 2025-06-30637,170USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-938,678USD91
2026-01-01 to 2026-06-30-2,186,581USD181
2025-04-01 to 2025-06-30-1,800,728USD91
2025-01-01 to 2025-06-30-2,898,669USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-301,368,884USD
At 2025-12-31567,874USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-307,707,145USD
At 2025-12-316,897,378USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2026-06-30931,972USD
At 2025-12-31716,220USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-04-01 to 2026-06-30938,678USD91
2026-01-01 to 2026-06-302,186,581USD181
2025-04-01 to 2025-06-301,858,208USD91
2025-01-01 to 2025-06-303,234,777USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-30131,130USD91
2026-01-01 to 2026-06-30464,464USD181
2025-04-01 to 2025-06-30880,835USD91
2025-01-01 to 2025-06-301,282,987USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-30420,279,879shares
At 2025-12-31420,279,879shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-06-30258,475,479USD
At 2025-12-31256,179,846USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2026-06-30-59,803USD
At 2025-12-31-60,191USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2026-06-30-6,287,564USD
At 2026-03-31-6,730,830USD
At 2025-12-31-6,302,718USD
At 2025-06-30-5,874,755USD
At 2025-03-31-5,068,981USD
At 2024-12-31-5,969,225USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2026-06-30102,549USD
At 2025-12-31126,628USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2026-06-30103,900USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2026-06-30120,945USD
At 2025-12-31120,013USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-06-30211,969USD
At 2025-12-31316,583USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-988,716USD91
2026-01-01 to 2026-06-30-2,289,665USD181
2026-01-01 to 2026-03-31-1,300,949USD90
2025-04-01 to 2025-06-30-1,852,081USD91
2025-01-01 to 2025-06-30-3,013,683USD181
2025-01-01 to 2025-03-31-1,161,602USD90

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-982,463USD91
2026-01-01 to 2026-06-30-2,272,632USD181
2025-04-01 to 2025-06-30-1,814,092USD91
2025-01-01 to 2025-06-30-2,954,148USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30807,548USD91
2026-01-01 to 2026-06-301,722,117USD181
2025-04-01 to 2025-06-30977,373USD91
2025-01-01 to 2025-06-301,951,790USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2026-01-01 to 2026-06-30932USD181
2025-01-01 to 2025-06-30932USD181

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2026-04-01 to 2026-06-3050,319USD91
2026-01-01 to 2026-06-30103,365USD181
2025-04-01 to 2025-06-3051,353USD91
2025-01-01 to 2025-06-30115,014USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-50,038USD91
2026-01-01 to 2026-06-30-103,084USD181
2025-04-01 to 2025-06-30-51,353USD91
2025-01-01 to 2025-06-30-115,014USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2026-01-01 to 2026-06-302,972USD181
2025-01-01 to 2025-06-304,305USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2026-01-01 to 2026-06-3075,000USD181
2025-01-01 to 2025-06-30700,000USD181

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2026-01-01 to 2026-06-3023,404USD181
2025-01-01 to 2025-06-3025,299USD181

Inspect the source

Entity
PROVECTUS BIOPHARMACEUTICALS, INC. / CIK 0000315545
Captured
2026-09-19T14:56:22.911Z
SEC response SHA-256
5c46f06a9f23badc21fb49ef63f53fb89ac39f7570babcbf8a64cddf67fb05d2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000315545.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))